One cycle = hypothesis generated by OmicsOS → experiment designed → executed via LabOS → data analyzed → validated insight confirmed. This is the fundamental unit of scientific value creation. Everything else derives from this.
The North Star captures both platform utilization and scientific rigor simultaneously. A company running 50 validated cycles per quarter is generating compounding scientific and commercial value. Secondary north star for investors: ARR Growth Rate.
| Metric | Year 1 | Year 2 | Year 3 | Year 5 |
|---|---|---|---|---|
| ARR | $500K | $3M | $10M | $50M+ |
| Active Customers | 5–8 | 20–30 | 60–80 | 200+ |
| Discovery Programs | 3–5 | 15–20 | 40–50 | 150+ |
| Closed-Loop Cycles/Qtr | 10 | 50 | 200 | 1,000+ |
| India Biomarker Atlas entries | 5,000 | 50,000 | 500K | 5M+ |
| Gross Margin | 40–50% | 55–65% | 65–70% | 75%+ |